Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patient with a diagnosis of detrusor overactivity associated with a neurological condition;~* Use clean intermittent catheterization~* On stable dose of oral oxybutynin before participation~Exclusion Criteria:~* Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency~* Have any medical condition that precludes their participation in the study or may confound the outcome of the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Oxybutynin Transdermal System (Type: EXPERIMENTAL): Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
- Oral oxybutynin (Type: ACTIVE_COMPARATOR): 5 to 15 mg/day immediate release or extended release tablets, or syrup

Based on this trial design, predict the completion outcome and termination type (if applicable).